AHA advertorial: 340B program advances health for patients and communities
As drug prices continue to rise, the 340B drug pricing program continues to help hospitals expand access to comprehensive health services, including lifesaving prescription drugs for those in need who may not be able to afford them, writes AHA President and CEO Rick Pollack in the Wall Street Journal.
“It is in the best interest of all to keep the 340B program strong so that our nation’s patients and communities can continue to receive the high-quality care and services on which they depend,” the advertorial adds.
Related News Articles
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…